Evidence map›Paper›PMID 27695033›Full record

SynthesisPloS one2016

An Empirical Biomarker-Based Calculator for Cystic Index in a Model of Autosomal Recessive Polycystic Kidney Disease-The Nieto-Narayan Formula.

Jake A Nieto, Michael A Yamin, Itzhak D Goldberg, Prakash Narayan

Erratum issuedOpen access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. International journal of ophthalmology · 2025
    Article
  2. Article
  3. Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jake A NietoDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.ORCID http://orcid.org/0000-0002-7007-0245
Michael A YaminDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Itzhak D GoldbergDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.
Prakash NarayanDepartment of Preclinical Research, Angion Biomedica Corp., Uniondale, New York, United States of America.ORCID http://orcid.org/0000-0002-7007-0245
Angion (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal recessive polycystic kidney disease (ARPKD) is associated with progressive enlargement of the kidneys fuelled by the formation and expansion of fluid-filled cysts. The disease is congenital and children that do not succumb to it during the neonatal period will, by age 10 years, more often than not, require nephrectomy+renal replacement therapy for management of both pain and renal insufficiency. Since increasing cystic index (CI; percent of kidney occupied by cysts) drives both renal expansion and organ dysfunction, management of these patients, including decisions such as elective nephrectomy and prioritization on the transplant waitlist, could clearly benefit from serial determination of CI. So also, clinical trials in ARPKD evaluating the efficacy of novel drug candidates could benefit from serial determination of CI. Although ultrasound is currently the imaging modality of choice for diagnosis of ARPKD, its utilization for assessing disease progression is highly limited. Magnetic resonance imaging or computed tomography, although more reliable for determination of CI, are expensive, time-consuming and somewhat impractical in the pediatric population. Using a well-established mammalian model of ARPKD, we undertook a big data-like analysis of minimally- or non-invasive blood and urine biomarkers of renal injury/dysfunction to derive a family of equations for estimating CI. We then applied a signal averaging protocol to distill these equations to a single empirical formula for calculation of CI. Such a formula will eventually find use in identifying and monitoring patients at high risk for progressing to end-stage renal disease and aid in the conduct of clinical trials.

Indexed as

BiomarkersAnimalsBlood Urea NitrogenChildCreatinineCystatin CCystsHepatitis A Virus Cellular Receptor 1HumansInterleukin-18KidneyKidney TransplantationLipocalin-2Magnetic Resonance ImagingMicePolycystic Kidney, Autosomal RecessiveBiomarkersCreatinineCystatin CHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1Interleukin-18Lipocalin-2

Identifiers

PMID27695033
PMCPMC5047475
OpenAlexW2530006799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.